January 9, 2017 / 1:53 PM / 8 months ago

BRIEF-PTC Therapeutics provides corporate update

Jan 9 (Reuters) - PTC Therapeutics Inc

* Preliminary 2016 translarna unaudited net sales of approximately $81 million

* Translarna 2017 net sales guidance of $105 to $125 million

* Topline act cf data anticipated late Q1 2017

* Non-GAAP operating expenses for 2017 are expected to be between $190 and $200 million

* PTC expects to finish 2017 with approximately $160 million of cash and cash equivalents Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below